Tissue engineering a surrogate niche for metastatic cancer cells

Seib, F. Philipp and Berry, Janice E. and Shiozawa, Yusuke and Taichman, Russell S. and Kaplan, David L. (2015) Tissue engineering a surrogate niche for metastatic cancer cells. Biomaterials, 51. pp. 313-319. ISSN 0142-9612 (https://doi.org/10.1016/j.biomaterials.2015.01.076)

[thumbnail of Sieb-etal-Biomaterials-2015-Tissue-engineering-a-surrogate-niche-for-metastatic]
Text. Filename: Sieb_etal_Biomaterials_2015_Tissue_engineering_a_surrogate_niche_for_metastatic.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (7MB)| Preview


In breast and prostate cancer patients, the bone marrow is a preferred site of metastasis. We hypothesized that we could use tissue-engineering strategies to lure metastasizing cancer cells to tissue-engineered bone marrow. First, we generated highly porous 3D silk scaffolds that were biocompatible and amenable to bone morphogenetic protein 2 functionalization. Control and functionalized silk scaffolds were subcutaneously implanted in mice and bone marrow development was followed. Only functionalized scaffolds developed cancellous bone and red bone marrow, which appeared as early as two weeks post-implantation and further developed over the 16-week study period. This tissue-engineered bone marrow microenvironment could be readily manipulated in situ to understand the biology of bone metastasis. To test the ability of functionalized scaffolds to serve as a surrogate niche for metastasis, human breast cancer cells were injected into the mammary fat pads of mice. The treatment of animals with scaffolds had no significant effect on primary tumor growth. However, extensive metastasis was observed in functionalized scaffolds, and the highest levels for scaffolds that were in situ manipulated with receptor activator of nuclear factor kappa-B ligand (RANKL). We also applied this tissue-engineered bone marrow model in a prostate cancer and experimental metastasis setting. In summary, we were able to use tissue-engineered bone marrow to serve as a target or "trap" for metastasizing cancer cells.